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Previously we have demonstrated that diabetes
causes impairment in vascular function of
epineurial vessels, which precedes the slowing
of motor nerve conduction velocity. Treatment
of diabetic rats with aldose reductase
inhibitors, aminoguanidine or myo-inositol
supplementation have been shown to improve
motor nerve conduction velocity and/or
decreased endoneurial blood flow. However,
the effect these treatments have on vascular
reactivity of epineurial vessels of the sciatic
nerve is unknown. In these studies we exam-
ined the effect of treating streptozotocin-
induced rats with sorbinil, aminoguanidine or
myo-inositol on motor nerve conduction veloc-
ity, endoneurial blood flow and endothelium-
dependent vascular relaxation of arterioles that
provide circulation to the region of the sciatic
nerve. Treating diabetic rats with sorbinil,
aminoguanidine or myo-inositol improved the
reduction of endoneurial blood flow and motor
nerve conduction velocity. However, only
sorbinil treatment significantly improved the
diabetes-induced impairment of acetylcholine-
mediated vasodilation of epineurial vessels of
the sciatic nerve. All three treatments were effi-
cacious in preventing the appropriate metabol-
ic derangements associated with either activa-
tion of the polyol pathway or increased nonen-
zymatic glycation. In addition, sorbinil was
shown to prevent the diabetes-induced decrease
in lens glutathione level. However, other mark-
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1560-4284/02 $12.00 + .00ers of oxidative stress were not vividly
improved by these treatments. These studies
suggest that sorbinil treatment may be more
effective in preventing neural dysfunction in
diabetes than either aminoguanidine or myo-
inositol.
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INTRODUCTION
Diabetic neuropathy is a multifactorial prob-
lem likely due to the poor control of hyper-
glycemia. Two of these perturbations are the
activation of the polyol pathway by which glu-
cose is metabolized to sorbitol via aldose reduc-
tase contributing to an alteration in the redox
balance and a decrease in myo-inositol uptake
and content and an increase in non-enzymatic
glycation leading to the abnormal glycation of
proteins [1,2]. In animal models of diabetes
prevention of these defects by treatment with
aldose reductase inhibitors, aminoguanidine or
supplementation with myo-inositol has been
shown to improve peripheral neuropathy.
Studies from numerous laboratories have
shown that treating diabetic rats with an aldose
reductase inhibitor improves nerve function as
well as endoneurial blood flow [3-12]. This has
led to wide speculation regarding the potential
benefit of aldose reductase inhibitor treatment
of diabetic complications [10-16]. However,
clinical trials using aldose reductase inhibitors
for treatment of diabetic neuropathy have been
disappointing [17]. Treatment of diabetic rats
with dietary myo-inositol has also been shown
to improve nerve function [18-21]. This led to
speculation 15 years ago that a common mech-
anism might induce the diverse complications
of diabetes [22]. However, more recent studies
have indicated that diabetic neuropathy is like-
ly due to multiple mechanisms involving hyper-
glycemia and decreased insulin and C-peptide
levels that effect both nerve and vascular tissue
[17].
Another mechanism thought to contribute to
diabetic complications is non-enzymatic glyca-
tion of proteins. Treatment of diabetic rats with
aminoguanidine, an inhibitor of the formation
of advanced glycosylation end products [23],
ameliorates the slowing of motor nerve con-
duction velocity and reduction of endoneurial
blood flow [24-28]. This suggests that the for-
mation of advanced glycation end products in
the nerve or vascular tissue perturbs neural
function [29-32].
Recently, Cameron et al. reported that dia-
betes causes a reduction in endoneurial blood
flow and that endoneurial hypoxia is an impor-
tant factor underlying nerve conduction deficits
early in the development of diabetic neuropa-
thy [33]. In their studies, they showed that
nerve blood flow was reduced as early as 1
week after diabetes induction. Moreover,
Wright and Nukada, and our laboratory have
shown that reductions in nerve blood flow pre-
ceded the decrease in nerve conduction veloci-
ties [34,35]. In addition, we have shown that
endothelial-dependent vasodilation of arteri-
oles that provide circulation to the region of the
sciatic nerve is impaired by diabetes and the
reduction in vascular function also precedes
slowing of motor nerve conduction velocity
[35,36]. These studies suggest that vascular
dysfunction is an important factor underlying
nerve conduction deficits and reduced
endoneurial blood flow early in the develop-
ment of diabetic neuropathy. This is supported
by earlier studies that demonstrated diabetes-
induced impairment in vasoreactivity in the sci-
atic nerve is due to reduced nitric oxide medi-
ated endothelium-dependent relaxation
[37,38].
In spite of the large number of studies
regarding the efficacy of treatment of diabetic
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aminoguanidine or myo-inositol on neural
activity little information is available on the
effects of these treatments on vascular reactivi-
ty. In studies using aldose reductase inhibitors,
treatment with tolrestat improved the impaired
response of the mesenteric circulation to hista-
mine and bradykinin caused by diabetes [39].
Aldose reductase inhibitor treatments have also
been shown to prevent the depression of
endothelium-dependent aortic relaxations
induced by diabetes, abnormalities in contrac-
tion and improve the synthesis of prostacyclin
by the aorta of diabetic rats [40-42]. In addi-
tion, in vitro studies using aortic rings incubat-
ed in 44 mM glucose demonstrated that hyper-
glycemia caused an aldose reductase inhibitor
and myo-inositol sensitive impairment in
endothelium-dependent vascular relaxation
[43,44]. Recently, Keegan et al. have demon-
strated that treating diabetic rats with the
aldose reductase inhibitor WAY121509 com-
pletely prevented the diabetes-induced decrease
in acetylcholine-induced relaxation in the cor-
pus cavernosum vascular bed [45]. In the aorta
from diabetic rats Archibald et al. and
Ozyazgan et al. have demonstrated that treat-
ment with aminoguanidine improved the dia-
betes-induced decrease in vascular relaxation
[46,47]. This could be due to a decrease in
advanced glycation end products, which have
been demonstrated to quench nitric oxide activ-
ity [48]. In contrast, treating diabetic rats with
aminoguanidine did not improve the diabetes-
induced impairment of vascular reactivity of
arterioles derived from striated muscle [49].
This suggests that improvement in vascular
reactivity by aminoguanidine treatment of dia-
betic rats may be dependent on the vascular
bed being examined. Even though many of the
studies presented above focused on the influ-
ence of treatment of diabetic rats with aldose
reductase inhibitors, aminoguanidine or myo-
inositol on nerve function, there is little infor-
mation available on the impact of these treat-
ments on the function of blood vessels that vas-
cularize the sciatic nerve. Since not all blood
vessels are alike it is important that this issue be
addressed. Thus, in the present study, using
streptozotocin-induced diabetic rats of 7-8
weeks duration, we examined the effect of dia-
betes and its treatment with sorbinil,
aminoguanidine or myo-inositol on endotheli-
um-dependent vascular relaxation of epineurial
vessels of the sciatic nerve, endoneurial blood
flow and motor nerve conduction velocity.
MATERIALS AND METHODS
Unless stated otherwise all chemicals used in
these studies were obtained from Sigma
Chemical Co. (St. Louis, MO). Sorbinil was a
generous gift from Pfizer Pharmaceutical Co.
Pentosidine standard was a kind gift from Dr.
Vincent Monnier.
ANIMALS
Male Sprague-Dawley (Harlan Sprague
Dawley, Indianapolis, IN) rats 8-9 weeks of age
were housed in a certified animal care facility
and food (Harlan Teklad, #7001, Madison,
WI) and water were provided ad libitum. All
institutional and NIH guidelines for use of ani-
mals were followed. Diabetes was induced by
intravenously injecting streptozotocin (60
mg/kg in 0.9% NaCl, adjusted to a pH 4.0 with
0.2 M sodium citrate). Control rats were inject-
ed with vehicle alone. The rats were anes-
thetized with halothane before injection.
Diabetes was verified 48h later by evaluating
blood glucose levels with the use of glucose-
oxidase reagent strips (Lifescan Inc., Milpitas,
CA). Rats having blood glucose level of 300
mg/dl (16.7 mM) or greater were considered to
be diabetic. At this time the diabetic rats were
randomly divided into four groups. The first
group received sorbinil as a dietary supplement
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myo-inositol as a dietary supplement 1% by
weight. The third group-received aminoguani-
dine delivered in the water at a dose of 1g/L.
The final group represented the untreated dia-
betic group. The sorbinil and myo-inositol was
added to a meal form of the diet that was
formed into pellets for feeding purposes.
Control, untreated diabetic, and diabetic rats
treated with aminoguanidine were fed non-sup-
plemented pelleted rat chow. The chow was
made in the laboratory, dried in a vacuum oven
and stored refrigerated until use. Water con-
taining aminoguanidine was made fresh weekly
and kept refrigerated. All studies were conduct-
ed approximately 7-8 weeks after the verifica-
tion of diabetes.
On the day of the experiment blood glucose
level was determined and the rats were anes-
thetized with Nembutal i.p. (50 mg/kg, i.p.,
Abbott Laboratories, North Chicago, IL).
Following the determination of motor nerve
conduction velocity (MNCV) and endoneurial
blood flow (EBF), the abdominal aorta was iso-
lated and occluded 1-2 cm above the branch of
the common iliac artery. The rat was then sac-
rificed by exsanguination, and body tempera-
ture lowered with topical ice. Samples of the
left sciatic nerve were then taken for determi-
nation of Na+/K+ ATPase activity and sorbitol,
fructose and myo-inositol content. The lens
was collected for determination of glutathione
levels. Serum samples were also taken for deter-
mination of thiobarbituric acid reactive sub-
stances (TBARS) and free fatty acids and
triglycerides.
MOTOR NERVE CONDUCTION VELOCITY
MNCV was determined as previously
described using a noninvasive procedure in the
sciatic-posterior tibial conducting system in a
temperature controlled environment [21,36].
ENDONEURIAL BLOOD FLOW
Immediately after determination of MNCV,
sciatic nerve endoneurial nutritive blood flow
was determined as described by Cameron et al.
[33,50]. The trachea was intubated for
mechanical ventilation and a carotid cannula
inserted to monitor mean arterial blood pres-
sure. Core temperature was monitored using a
rectal probe and temperature regulated
between 36 and 37oC using a heating pad and
radiant heat. The right sciatic nerve was care-
fully exposed by a small surgical incision and
the surrounding skin sutured to a plastic ring.
The isolated area was filled with mineral oil at
37oC to a depth of 1 cm to minimize diffusion
of hydrogen gas from the nerve. The rats were
then mechanically ventilated. A glass insulated
platinum microelectrode (tip = 2 µm) was
inserted into the sciatic nerve, proximal to the
trifurcation, and polarized at 0.25 V with
respect to a reference electrode inserted subcu-
taneously into the flank of the rat. Once the
recording had stabilized, the inspired air was
modified to contain 10% hydrogen gas and this
gas flow continued until the hydrogen current
recorded by the electrode had stabilized, indi-
cating equilibrium of the inspired air with arte-
rial blood. The hydrogen gas supply was then
discontinued and the hydrogen clearance curve
recorded until a baseline was achieved. The
hydrogen clearance data was fitted to a mono-
or bi-exponential curve using commercial soft-
ware (Prism, GraphPad, San Diego, CA) and
nutritive blood flow, (ml/min/100g), calculated
using the equation described by Young [51] and
vascular conductance, (ml/min/100g/mm Hg)
determined by dividing nutritive blood flow by
the average mean arterial blood pressure. Two
recordings were made for each rat at different
locations along the nerve and the final blood
flow value averaged.
VASCULAR REACTIVITY
Videomicroscopy was used to investigate in
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vascularizing the region of the sciatic nerve
(branches of the superior gluteal and internal
pudendal arteries) as previously described
[35,36]. The vessels used for these studies were
generally oriented longitudinally in relation to
the sciatic nerve; however, on occasion radially
oriented vessels were also used. No differences
were observed in acetylcholine-induced vasodi-
lation based on the orientation of the vessel to
the sciatic nerve. The arterioles used in this
study should be regarded as epineurial rather
than perineurial vessels. Cumulative concentra-
tion-response relationships were evaluated for
acetylcholine (10-8–10-4 M) using vessels from
control and untreated and treated diabetic rats.
At the end of each acetylcholine dose response
determination sodium nitroprusside (10-4 M)
was added to determine maximal vasodilation.
DETECTION OF SUPEROXIDE
Hydroethidine (Molecular Probes Inc.,
Eugene, OR), an oxidative fluorescent dye, was
used to evaluate in situ levels of superoxide (O2
-)
as described previously [35,52]. Hydroethidine
is permeable to cells and in the presence of O2
-
is oxidized to fluorescent ethidium bromide,
where it is trapped by intercalating with DNA.
This method provides sensitive detection of O2
-
in situ. Unfixed frozen ring segments were cut
into 5-µm-thick sections and placed on glass
slides. Hydroethidine (2x10-6 M) was topically
applied to each tissue section and cover slipped.
Slides were incubated in a light protected
humidified chamber at 37oC for 30 minutes.
Images were obtained with a Bio-Rad MRC-
1024 laser scanning confocal microscope
equipped with a krypton/argon laser.
Fluorescence was detected with a 585-nm long
pass filter. Tissue from control and untreated
and treated diabetic rats were processed and
imaged in parallel. Laser settings were identical
for acquisition of all images from control and
diabetic specimens.
SCIATIC NERVE SORBITOL, FRUCTOSE AND
MYO-INOSITOL CONTENT AND RETINA
PENTOSIDINE LEVEL
As a marker of sorbinil and myo-inositol
treatment efficacy the level of sciatic nerve sor-
bitol, fructose and myo-inositol was deter-
mined. Briefly, the left sciatic nerve was
removed, desheathed, and divided into two
samples for determination of Na+/K+ ATPase
activity and sorbitol, fructose and myo-inositol
content [35]. For the determination of sorbitol,
fructose and myo-inositol content the nerve
sample was weighed, derivatized and analyzed
by gas-liquid chromatography as previously
described [21,36]. To determine aminoguani-
dine efficacy the pentosidine content of the reti-
na was determined by high performance liquid
chromatography coupled with fluorescence
detection as described by Sell and Monnier
[53].
NA+/K+ ATPASE ACTIVITY
Total and ouabain-inhibited Na+/K+ ATPase
activities were measured in crude homogenates
of sciatic nerve [21,36]. Sciatic nerves were
homogenized in a glass homogenizer at 4oC in
1 ml of 0.2 M sucrose, 0.02 M Tris-HCl buffer,
pH 7.5. The samples were then centrifuged at
100-x g for 10 min at 4oC. An aliquot of the
supernatant (50 µl) was added to two cuvettes
containing 100 mM NaCl, 10 mM KCl, 2.5
mM MgCl2, 2 mM ethylene glycol-bis(β-
aminoethyl ether)-N1-N’-tetraacetic acid
(EGTA), 1 mM Tris-ATP, 1 mM 3-(cyclohexy-
lammonium) phosphoenolpyruvate (Boehringer-
Mannheim, Indianapolis, IN), 30 mM imida-
zole-HCl buffer (pH 7.3), 0.15 mM NADH, 50
µg lactate dehydrogenase (Boehringer-
Mannheim, Indianapolis, IN), 30 µg pyruvate
kinase (Boehringer-Mannheim, Indianapolis,
IN) with or without 1 mM ouabain to inhibit
the ouabain-sensitive Na+/K+ ATPase fraction.
After a 20 min stabilization period, the oxida-
tion of NADH was recorded over a 30 min
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ADP/g wet weight/h. Each assay was conduct-
ed in triplicate.
ADDITIONAL BIOLOGICAL PARAMETERS
Lens glutathione (GSH) and serum TBARS
levels were determined as additional markers of
oxidative stress. Lens glutathione levels were
determined according to Lou et al. [54]. Lens
were weighed and homogenized in 1 ml of cold
10% trichloroacetic acid and centrifuged for 15
min at 1000-x g. The supernatant (100 µl) was
mixed with 0.89 ml of 1.0 M Tris, pH 8.2, and
0.02 M EDTA. Afterwards, 10 µl of dithioni-
trobenzene (DTNB) was added and change in
absorbance measured at 412 nm. A glutathione
standard curve (100-500 ng) was performed for
each assay. The data were recorded as µg/mg
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TABLE I  Change in Body Weight and Blood Glucose Levels
Animal  Change in Body Weight (g)  Blood glucose mg/dl  
Control (n = 7)  195 ± 17 88  ± 7  
Diabetic (n = 7)  39 ± 16+  390 ± 22+ 
Diabetic + sorbinil  40 ± 14+  430 ± 22+ 
(n = 11)
Diabetic + myo-inositol 43 ± 14+ 425 ± 21+
(n = 9)
Diabetic + aminoguanidine 24 ± 9+  427 ± 17+ 
(n = 11) 
Data are means ± S.E.M.
+ p < 0.05 vs control
TABLE II  Effect of Treatment of Streptozotocin-induced Diabetic Rats with Sorbinil, myo-Inositol or Aminoguanidine 
on Sciatic Nerve Na+/K+ ATPase activity and Sorbitol, Fructose and myo-Inositol Levels
Animal Na+/K+ ATPase activity  Intracellular content (nmol/mg wet weight)
(µmol ADP/g wet weight)  ________________________________________________
Sorbitol Fructose myo-Inositol
Control (n = 7)    296.7 ± 22.9 0.2  ± 0.1 0.8  ± 0.1 10.4  ± 2.1  
Diabetic (n = 7)    129.6 ± 25.2+  0.8 ± 0.1+  3.4 ± 0.2+  4.7 ± 0.6+ 
Diabetic + sorbinil  207.8± 27.5*  0.3 ± 0.1*  1.4 ± 0.3*  8.9 ± 1.0*
(n = 11)   
Diabetic + myo-inositol  186.9± 9.8* 0.9 ± 0.3+ 3.3 ± 0.4+ 9.6 ± 0.3*
(n = 9)
Diabetic + aminoguanidine  111.6 ± 20.3+ 1.1 ± 0.2+  4.6 ± 0.6+  6.1 ± 1.1+
(n = 11) 
Data are means ± S.E.M.
+ p < 0.05 vs control
* p < 0.05 vs diabeticwet weight. TBARS level in serum was deter-
mined by the method of Mihara et al. [55] as
modified by Siman and Eriksson [56]. Briefly,
200 µl of serum was boiled in 0.75 ml of phos-
phoric acid (0.19 M), 0.25 ml thiobarbituric
acid (0.42 mM) and 0.3 ml water for 60 min.
Afterwards, the samples were precipitated with
methanol/NaOH and centrifuged for 5 min.
The supernatant was measured fluorometrical-
ly at excitation wavelength of 532 nm and
emission wavelength of 553 nm. Standards
were prepared by the acid hydrolysis of
1,1,3,3-tetraethoxypropane. The data was
reported as µg/ml serum. Serum free fatty acid
and triglyceride levels were determined using
commercial kits from Roche Diagnostics,
Mannheim, Germany and Sigma Chemical Co.,
St. Louis, MO, respectively.
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FIGURE 1
Detection of superoxide level in epineurial vessels from control, diabetic rats and diabetic rats treated with sorbinil, myo-inositol or
aminoguanidine. Fluorescent photomicrographs of confocal microscopic sections of arterioles that provide circulation to the region of
the sciatic nerve from the five individual groups of animals were examined on the same day. Arterioles were labeled with the oxidative
dye hydroethidine as described in the Methods section. Recording of fluorescent were taken at identical laser and photomultiplier set-
tings for both control and untreated and treated diabetic rats. Shown is a representative sample of one set of animals. This experiment
was repeated four separate times on separate sets of animals with similar results.DATA ANALYSIS
The results are presented as mean ± SE.
Comparisons between the groups for MNCV,
EBF, sciatic nerve Na+/K+ ATPase activity, sciat-
ic nerve sorbitol, fructose and myo-inositol
content, serum TBARS, serum free fatty acid
and triglyceride and lens glutathione levels
were conducted using independent unpaired
Student’s t tests. Dose response curves for
acetylcholine-induced relaxation were com-
pared using a two way repeated measures
analysis of variance with autoregressive covari-
ance structure using proc mixed program of
SAS [35,36]. Whenever significant interactions
were noted specific treatment-dose-effects were
analyzed using a Bonferroni adjustment. A p
value of less 0.05 was considered significant.
All computations were performed using SAS
for Windows version 6.12.
RESULTS
BODY WEIGHT AND PLASMA GLUCOSE LEVELS
Data in Table I show that streptozotocin-
induced diabetic rats treated or untreated
gained less weight than age-matched control
rats over the 7-8 week period of this study. At
the time of experimentation plasma glucose lev-
els were increased 4-fold in treated or untreat-
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FIGURE 2
Determination of the effect of treatment of diabetic rats with sorbinil, myo-inositol or aminoguanidine on acetylcholine-mediated vas-
cular relaxation in arterioles that provide circulation to the region of the sciatic nerve. Pressurized arterioles were constricted with
U46619 (30-50%) and incremental doses of acetylcholine were added to the bathing solution while recording steady state vessel diam-
eter. The number of experimental animals used in these studies was the same as noted in Table I. The + denotes that the response to
acetylcholine was significantly attenuated in the diabetic rats compared to control rats. The * denotes that the response to acetylcholine
was significantly different compared to the untreated diabetic rats.ed diabetic rats compared to control rats.
Treating diabetic rats with sorbinil, myo-inosi-
tol or aminoguanidine had no significant effect
on weight gain or blood glucose level compared
to untreated diabetic rats.
SCIATIC NERVE NA+/K+ ATPASE ACTIVITY
AND SORBITOL, FRUCTOSE AND
MYO-INOSITOL CONTENT
Data in Table II demonstrate that diabetes
causes a significant decrease in sciatic nerve
Na+/K+ ATPase activity. Treating diabetic rats
with sorbinil or myo-inositol significantly
improved sciatic nerve Na+/K+ ATPase activity.
In contrast, treating diabetic rats with
aminoguanidine did not prevent the diabetes-
induce decrease in Na+/K+ ATPase activity. Data
in Table II also demonstrate that diabetes caus-
es a significant increase in the sorbitol and fruc-
tose content in the sciatic nerve and a decrease
in the myo-inositol content. Treating diabetic
rats with sorbinil corrected this defect, whereas
treating diabetic rats with myo-inositol only
corrected the myo-inositol content in the sciatic
nerve. Treating diabetic rats with aminoguani-
dine does not correct the changes in sorbitol,
fructose or myo-inositol levels in the sciatic
nerve. The latter data demonstrate the efficacy
of the sorbinil and myo-inositol treatment of
the diabetic rats. Retina pentosidine level was
increased approximately 4-fold by diabetes and
was totally prevented by treatment with
aminoguanidine, thereby demonstrating the
efficacy of the aminoguanidine treatment (data
not shown).
SERUM TRIGLYCERIDE AND FREE FATTY
ACID LEVELS
Data in Table III demonstrate that diabetes
causes a significant increase in serum free fatty
acid and triglyceride levels, which was not
affected by treatment with sorbinil, myo-inosi-
tol or aminoguanidine.
EVALUATION OF OXIDATIVE STRESS
In order to assess the effect of diabetes and
its treatment with sorbinil, myo-inositol or
aminoguanidine on oxidative stress, we exam-
ined three different markers of oxidative stress
in several different tissues. By examining multi-
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TABLE III Effect of Treatment of Streptozotocin-induced Diabetic Rats with Sorbinil, myo-Inositol or Aminoguanidine 
on Serum Free Fatty Acid, Triglyceride and Thiobarbituric Acid Reactive Substances (TBARS) and Lens Glutathione Levels
Animal  Serum  Lens    
Free Fatty Acid Triglyceride TBARS Glutathione
(mmol/l) (mg/dl) (µg/ml) (µg/mg wet wt)
Control (n = 7)     0.10 ± 0.01 69  ± 7 8.2  ± 1.2 1.46  ± 0.09  
Diabetic (n = 7)     0.70 ± 0.06+  543 ± 172+  20.2 ± 2.3+  0.32 ± 0.08+
Diabetic + sorbinil (n = 11)     0.68 ± 0.05+  448 ± 77+  15.3 ± 1.5+  1.30 ± 0.11* 
Diabetic + myo-inositol  0.67 ± 0.05+ 473 ± 125+ 14.3 ± 1.8+* 0.25 ± 0.04+
(n = 9)
Diabetic + aminoguanidine  1.13 ± 0.28+ 353 ± 47+  16.2 ± 1.2+  0.28 ± 0.05+
(n = 11) 
Data are means ± S.E.M.
+ p < 0.05 vs control
* p < 0.05 vs diabeticple markers of oxidative stress we hoped to get
a better understanding of the oxidative stress
status of the diabetic rats and the effect of treat-
ment with sorbinil, myo-inositol or
aminoguanidine. Data in Table III demonstrate
that diabetes causes a significant increase in
thiobarbituric acid reactive substances
(TBARS) in serum. Treating diabetic rats with
sorbinil, myo-inositol or aminoguanidine did
not affect the increase in serum TBARS level
caused by diabetes. Data in Table III also
demonstrate that lens glutathione level was sig-
nificantly decreased in streptozotocin-induced
diabetic rats compared to control rats. Treating
diabetic rats with myo-inositol or aminoguani-
dine did not improve the decrease in lens glu-
tathione level induced by diabetes. In contrast,
treating diabetic rats with sorbinil significantly
improved lens glutathione level.
We have previously reported that diabetes
causes an increase in superoxide level in arteri-
oles that provide circulation to the region of the
sciatic nerve [35]. The increase in superoxide
level was observed in endothelial cells as well as
in the smooth muscle and adventitial cells. In
these studies we sought to determine whether
treating diabetic rats with sorbinil, myo-inosi-
tol or aminoguanidine prevented the increase in
superoxide level observed in vascular tissue.
Data in Figure 1 demonstrate that treating
streptozotocin-induced diabetic rats with
sorbinil, myo-inositol or aminoguanidine did
not prevent the diabetes-induced increase in the
level of superoxide in epineurial vessels as
measured by hydroethidine fluorescence com-
pared to paired analysis of untreated diabetic
rats. The apparent small improvement in super-
oxide level in epineurial vessels from diabetic
rats treated with sorbinil or aminoguanidine
was vividly less than observed following treat-
ment with antioxidants [52,57].
ENDONEURIAL BLOOD FLOW AND MOTOR NERVE
CONDUCTION VELOCITY
As previously reported, diabetes causes a
reduction in EBF and slowing of MNCV in the
sciatic nerve conducting system [35,36]. Data
in Table IV demonstrate that treating diabetic
rats with sorbinil, myo-inositol or aminoguani-
dine prevents the decrease in EBF and MNCV
compared to untreated diabetic rats.
ARTERIOLAR VASCULAR REACTIVITY
Stimulated changes in vascular diameter of
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TABLE IV  Effect of Treatment of Streptozotocin-induced Diabetic Rats with Sorbinil, myo-Inositol or Aminoguanidine 
on Endoneurial Blood Flow and Motor Nerve Conduction Velocity (MNCV)
Animal Endoneurial  MNCV
Blood Flow (m/sec) 
Nutritive Conductance
(ml/min/100 g)  (ml/min/100 g/mm Hg) 
Control (n = 7)  19.2 ± 2.6 0.15  ± 0.02 60.2  ± 3.0   
Diabetic (n = 7)  6.8 ± 1.2+  0.06 ± 0.01+  41.3 ± 1.3+ 
Diabetic + sorbinil (n = 11)  16.3 ± 4.1*  0.14 ± 0.04*  49.7 ± 1.6*+ 
Diabetic + myo-inositol (n = 9) 15.8 ± 2.1* 0.13 ± 0.02* 52.0 ± 2.4*+
Diabetic + aminoguanidine (n = 11)  18.1 ± 2.9* 0.16 ± 0.03*  51.0 ± 1.6*+
Data are means ± S.E.M.
+ p < 0.05 vs control
* p < 0.05 vs diabeticarterioles that provide circulation to the region
of the sciatic nerve were measured in vitro by
application of acetylcholine (endothelium-
dependent) as previously described [35,36].
Baseline diameter of vessels from control and
diabetic rats (untreated or treated) was similar
and the vessels were constricted to a similar
degree with U46619 (10-100nM). As previous-
ly reported, and as demonstrated in Figure 2,
diabetes causes a significant decrease in acetyl-
choline mediated vascular relaxation in arteri-
oles that provide circulation to the region of the
sciatic nerve. Treating diabetic rats with
sorbinil significantly improved by about 50%
the diabetes-induced impairment in acetyl-
choline mediated vascular relaxation. In con-
trast, treating diabetic rats with myo-inositol or
aminoguanidine did not improve acetylcholine
mediated vascular relaxation. Maximal vascu-
lar relaxation induced by 10-4 M sodium nitro-
prusside (endothelium-independent) in these
vessels was significantly reduced by diabetes
(99.5 ± 2.1 vs 76.2 ± 5.7 for control and dia-
betic rats, respectively, p < 0.05). Treating dia-
betic rats with sorbinil, myo-inositol or
aminoguanidine did not significantly improve
maximal vascular relaxation induced by 10-4 M
sodium nitroprusside (86.3 ± 4.6, 75.4 ± 3.9
and 76.3 ± 4.9, respectively, p < 0.05 compared
to control).
DISCUSSION
Diabetic neuropathy is a heterogeneous dis-
ease with a widely varying pathology and mul-
tiple etiologies including metabolic, vascular,
autoimmune, oxidative stress, and neurohor-
monal growth-factor deficiency components
[58]. Among the metabolic factors that poten-
tially contribute to the development of diabetic
neuropathy the polyol pathway and nonenzy-
matic glycation have been extensively studied
[59]. Based on these studies pharmacological
compounds, like aldose reductase inhibitors
and anti-glycation agents, have been developed
for the treatment of diabetic neuropathy [59].
In diabetic animal models these agents have
been shown to improve nerve function and
endoneurial blood flow [3-12,24-28].
However, studies on the effect these agents may
have on vascular function of vessels that pro-
vide circulation to nerves have been limited. We
have previously shown that endothelial-
dependent vascular relaxation of arterioles that
provide circulation to the region of the sciatic
nerve is impaired by diabetes [35,36]. In the
present study we sought to determine the effect
treatment of diabetic rats with sorbinil, an
aldose reductase inhibitor, aminoguanidine, an
inhibitor of nonenzymatic glycation, or myo-
inositol supplementation has on EBF, MNCV
as well as vascular relaxation of arterioles that
provide circulation to the region of the sciatic
nerve.
As has been previously reported, we demon-
strate that treating streptozotocin-induced dia-
betic rats with sorbinil or aminoguanidine sig-
nificantly improves the reduction in EBF and
slowing of MNCV [3-12,24-28]. In sorbinil
treated diabetic rats EBF and MNCV remained
suppressed by 15 and 18%, respectively com-
pared to controls, whereas in aminoguanidine
treated rats EBF and MNCV, compared to con-
trols, was decreased by 6 and 16%, respective-
ly. This indicates that aminoguanidine treat-
ment was more effective than sorbinil in
improving EBF. This could be interpreted as
meaning that pathways inhibited by
aminoguanidine in diabetic rats such as
increased nonenzymatic glycation could have a
greater impact on reducing EBF than increased
aldose reductase activity. However, the efficacy
of these treatments could also be different. The
dose of sorbinil used in our studies did not
completely prevent the diabetes-induced
increase in sorbitol and fructose levels in the
sciatic nerve suggesting that we did not achieve
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our studies, which could have an impact on the
differences observed in the efficacy of these
treatments. Dietary myo-inositol supplementa-
tion also improved the slowing of MNCV as
previously reported as well as EBF [18-21]. The
latter result was unexpected since Cameron et
al. [9] has reported that aldose reductase
inhibitor treatment of diabetic rats improves
the reduction in EBF and MNCV independent
of nerve myo-inositol levels. In contrast,
Stevens et al. [60] has reported that myo-inosi-
tol supplementation improves EBF in diabetic
rats. Therefore, the role of myo-inositol defi-
ciency in the development of diabetic neuropa-
thy remains controversial [61]. Clinically, myo-
inositol supplementation has proved disap-
pointing and no trials have shown any
improvement in nerve function [62].
Treatment of diabetic rats with aminoguani-
dine or myo-inositol did not improve the dia-
betes-induced impairment in acetylcholine-
mediated vascular relaxation in arterioles that
provide circulation to the region of the sciatic
nerve, suggesting that neither treatment is effi-
cacious in preventing diabetic vascular disease
in this vascular bed as it relates to diabetic neu-
ropathy. In contrast, our studies demonstrated
that sorbinil treatment of diabetic rats signifi-
cantly improved vascular reactivity in epineur-
ial vessels. This agrees with previous studies
that demonstrated that treating diabetic rats
with an aldose reductase inhibitor improved
relaxation in the aorta, corpus cavernosum and
mesenteric vascular beds [42,45]. The observa-
tion that treatment of diabetic rats with
aminoguanidine or myo-inositol corrects EBF
without improving vascular reactivity of
epineurial vessels is intriguing. This would sug-
gest that regulation of EBF is not completely
dependent upon vascular relaxation of epineur-
ial vessels and that reduced EBF can be
improved in diabetic animal models independ-
ent of correction of vascular function of
epineurial vessels. The mechanism responsible
for this phenomenon is unknown but could
include differences of the effect of hyper-
glycemia/diabetes on the vascular function of
epineurial vessels compared to endoneurial ves-
sels. One possibility could be the effect of
hyperglycemia/diabetes on the vascular smooth
muscles of epineurial vessels and the anatomi-
cal differences between epineurial and
endoneurial vessels. In this regard, it has been
reported that epineurial and perineurial vessels
are less significantly diseased than endoneurial
vessels in diabetes [63].
In agreement with our studies, Crijns et al.
[49] found that treating diabetic rats with
aminoguanidine had no beneficial effect on the
reduction of endothelium-dependent vasodila-
tion of arterioles derived from striated muscle.
This contrasts with previous studies that
demonstrated that aminoguanidine treatment
of diabetic rats improved vasodilation in the
aorta [46,47]. In addition, Cartledge et al. [64]
have demonstrated that the formation of
advanced glycation endproducts is probably
responsible for the impairment of endothelial-
dependent penile smooth muscle relaxation
seen in diabetes. This suggests that the mecha-
nisms responsible for vascular dysfunction in
diabetes may be partially dependent on the vas-
cular bed. In contrast, to the lack of a beneficial
effect of aminoguanidine or myo-inositol treat-
ment of diabetic rats on vascular function
observed in our studies of epineurial vessels,
treating diabetic rats with sorbinil improved
acetylcholine-mediated vascular relaxation by
about 50%. Other studies have demonstrated
that diabetes-induced impairment of vascular
reactivity in the corpus cavernosum, mesentery,
and aorta are corrected by treatment with
aldose reductase inhibitors [39,40,42,45].
Interestingly, sorbinil treatment restored lens
glutathione levels to normal and improved the
reduction in sciatic nerve sorbitol, fructose and
myo-inositol content and Na+/K+ ATPase activ-
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sorbinil treatment could be of significance since
Bravenboer et al. [65] have demonstrated that
glutathione, a free radical scavenger, is partial-
ly effective in preventing diabetic neuropathy in
streptozotocin-induced diabetic rats. In con-
trast, sorbinil treatment of diabetic rats did not
improve other markers of oxidative stress such
as serum TBARS level or epineurial vessel
superoxide level. As mentioned above, the
sorbinil dosage used in our studies did not
totally correct the diabetes-induced increase in
sorbitol levels in the sciatic nerve or the
decrease in myo-inositol. In future studies it
would be important to determine whether
complete inhibition of aldose reductase with
either a higher concentration of sorbinil or use
of a more potent aldose reductase inhibitor
may further improve vascular function and per-
haps other markers of oxidative stress. Treating
diabetic rats with aminoguanidine did not
improve any of the sciatic nerve metabolic
abnormalities or markers of oxidative stress.
The latter finding is surprisingly since many of
the effects of increased nonenzymatic glycation
and the formation of advanced glycation end
products has been attributed to increasing
oxidative stress [31,32]. However, much of this
could be due to our lack of understanding the
source of superoxide production in diabetes
and the effects of these treatments. Treating
diabetic rats with myo-inositol did not improve
any of the markers for oxidative stress but did
improve sciatic nerve myo-inositol levels and
Na+/K+ ATPase activity. 
Previously we have demonstrated that treat-
ing diabetic rats with two different antioxi-
dants, α-lipoic acid or M40403, prevented the
reduction in EBF, MNCV and impairment of
vascular relaxation of epineurial vessels
[52,57]. Treatment with these antioxidants pre-
vented the generation of superoxide and perox-
ynitrite in epineurial vessels and the aorta and
the increase in serum TBARS but did not cor-
rect the metabolic derangements of the sciatic
nerve. Form these studies we concluded that
diabetes-induced oxidative stress and the gener-
ation of superoxide and perhaps peroxynitrite
may be partially responsible for the develop-
ment of diabetic vascular and neural complica-
tions. The present study demonstrated that
treatment of streptozotocin-induced diabetic
rats with sorbinil prevented the metabolic
derangements in the sciatic nerve as well as the
reduction of glutathione in the lens. These
defects were not uniformly corrected by treat-
ment with antioxidants [52,57]. Thus, treat-
ment protocols utilizing the combination of
antioxidants and aldose reductase inhibitors
may be an effective approach in preventing dia-
betic vascular and neural disease.
Acknowledgments
This work was supported by a National
Institute of Diabetes and Digestive and Kidney
Diseases Grant DK-25295, by a grant from the
National Institute of Diabetes and Digestive
and Kidney Diseases DK-58005, by a Diabetes
Center Grant from the Veterans Affairs and
International Juvenile Diabetes Foundation,
and by a research grant from the American
Diabetes Association.
REFERENCES
1. Tomlinson, D. (1998) Future prevention and treatment of
diabetic neuropathy, Diabetes & Metabolism, 24, 79-83.
2. Akbari, C.M. and LoGerfo, F.W. (1999) Diabetes and
peripheral vascular disease, J. Vasc. Surg., 30, 373-384.
3. Finegold, D., Lattimer, S.A., Nolle, S., Bernstein, M. and
Greene, D.A. (1983) Polyol pathway activity and myo-
inositol metabolism, Diabetes, 32, 988-992.
4. Mayer, J.H. and Tomlinson, D.R. (1983) Prevention of
defects of axonal transport and nerve conduction velocity
by oral administration of myo-inositol or an aldose reduc-
tase inhibitor in streptozotocin-diabetic rats, Diabetologia,
25, 433-438.
5. Tomlinson, D.R., Moriaity, R.J. and Heidi Mayer, J.
(1984) Prevention and reversal of defective axonal trans-
VASCULAR DYSFUNCTION IN DIABETIC NEUROPATHY 33
I NTERNATIONAL J OURNAL OF E XPERIMENTAL D IABETES R ESEARCHport and motor nerve conduction velocity in rats with
experimental diabetes by treatment with the aldose reduc-
tase inhibitor sorbinil, Diabetes, 33, 470-476.
6. Greene, D.A. and Lattimer, S.A. (1984) Action of sorbinil
in diabetic peripheral nerve, Diabetes, 33, 712-716.
7. Kikkawa, R., Hatanaka, I., Yasuda, H., Kobayashi, N. and
Shigeta, Y. (1984) Prevention of peripheral nerve dysfunc-
tion by an aldose reductase inhibitor in streptozotocin-dia-
betic rats, Metabolism, 33, 212-214.
8. Sima, A.A.F., Prashar, A., Zhang, W-X., Chakrabarti, S.
and Greene, D.A. (1990) Preventive effect of long-term
aldose reductase inhibition (Ponalrestat) on nerve conduc-
tion and sural nerve structure in the spontaneously diabet-
ic bio-breeding rat, J. Clin. Invest., 85, 1410-1420.
9. Cameron, N.E., Cotter, M.A., Dines, K.C., Maxfield, E.K.,
Carey, F. and Mirrlees, D.J. (1994) Aldose reductase inhi-
bition, nerve perfusion, oxygenation and function in strep-
tozotocin-diabetic rats: dose-response considerations and
independence from a myo-inositol mechanism,
Diabetologia, 37, 651-663.
10. Hirata, Y., Fujimori, S. and Okada, K. (1988) Effect of a
new aldose reductase inhibitor, 8’-Chloro-2’,3’-
Dihydrospiro[Pyrrolidine-3,6’(5’H)-Pyrrolol[1,2,3-
de][1,4]Benzoxamine]-2,5,5’-Trione (ADN-138), on
delayed motor nerve conduction velocity in streptozotocin-
diabetic rats, Metabolism, 37, 159-163.
11. Cameron, N.E. and Cotter, M.A. (1992) Dissociation
between biochemical and functional effects of the aldose
reductase inhibitor, ponalrestat, on peripheral nerve in dia-
betic rats, Br. J. Pharmacol., 107, 939-944.
12. Yoshida, T., Nishioka, H., Yoshioka, K., Nakano, K.,
Kondo, M. and Terashima, H. (1987) Effect of aldose
reductase inhibitor ONO 2235 on reduced sympathetic
nervous system nerve disorders in STZ-induced diabetic
rats, Diabetes, 36, 6-13.
13. Tomlinson, D.R., Stevens, E.J. and Diemel, L.T. (1994)
Aldose reductase inhibitors and their potential for the
treatment of diabetic complications, TiPS, 15, 293-297.
14. Hotta, N. (1995) New approaches for treatment in dia-
betes: aldose reductase inhibitors, Biomed. &
Pharmacother., 5, 232-243.
15. Yabe-Nishimura, C. (1998) Aldose reductase in glucose
toxicity: a potential target for the prevention of diabetic
complications, Pharmacological Rev., 50, 21-33.
16. Crabbe, M.J.C. and Goode, D. (1998) Aldose reductase: a
window to the treatment of diabetic complications?, Prog.
Retinal Eye Res., 17, 313-383.
17. Sugimoto, K., Murakawa, Y. and Sima, A.A.F. (2000)
Diabetic neuropathy- a continuing enigma,
Diabetes/Metabolism Res. Rev., 16, 408-433.
18. Greene, D.A., De Jesus, P.V. Jr. and Winegrad, A.I. (1975)
Effects of insulin and dietary myoinositol on impaired
peripheral motor nerve conduction velocity in acute strep-
tozotocin diabetes, J. Clin. Invest., 55, 1326-1336.
19. Greene, D.A., Lewis, R.A., Lattimer, S.A. and Brown, M.J.
(1982) Selective effects of myo-inositol administration on
sciatic and tibial motor nerve conduction parameters in the
streptozotocin-diabetic rat, Diabetes, 31, 573-578.
20. Greene, D.A., Chakrabarti, S., Lattimer, S.A. and Sima,
A.A.F. Role of sorbitol accumulation and myo-inositol
depletion in paranodal swelling of large myelinated nerve
fibers in the insulin-deficient spontaneously diabetic bio-
breeding rat, J. Clin. Invest., 79, 1479-1485.
21. Yorek, M.A., Wiese, T.J. Davidson, E.P., Dunlap, J.A.
Stefani, M.R., Conner, C.E., Lattimer, S.A., Kamijo, M.
Greene, D.A. and Sima, A.A.F. (1993) Reduced motor
nerve conduction velocity and Na+ -K+ -ATPase activity in
rats maintained on L-fucose diet, Diabetes, 42, 1401-1406.
22. Winegrad, A.I. (1987) Does a common mechanism induce
the diverse complications of diabetes?, Diabetes, 36, 396-
406.
23. Nilsson, B.-O. (1999) biological effects of aminoguanidine:
an update, Inflamm. Res., 48, 509-515.
24. Kihara, M., Schmelzer, J.D., Poduslo, J.F., Curran, G.L.,
Nickander, K.K. and Low, P.A. (1991) Aminoguanidine
effects on nerve blood flow, vascular permeability, electro-
physiology, and oxygen free radicals, Proc. Natl. Acad.
Sci., 88, 6107-6111.
25. Cameron, N.E., Cotter, M.A., Dines, K. and Love, A.
(1992) Effects of aminoguanidine on peripheral nerve
function and polyol pathway metabolites in streptozo-
tocin-diabetic rats, Diabetologia, 35, 946-950.
26. Miyauchi, Y., Shikama, H., Takasu, T., Okamiya, H.,
Umeda, M., Hirasaki, E., Ohhata, I., Nakayama, H. and
Nakagawa, S. (1996) Slowing of peripheral motor nerve
conduction was ameliorated by aminoguanidine in strepto-
zotocin-induced diabetic rats, European J. Endo., 134,
467-473.
27. Monnier, V.M. (1996) Aminoguanidine and diabetic neu-
ropathy, European J. Endo., 134, 398-400.
28. Dewhurst, M., Omawari, N. and Tomlinson, D.R. (1997)
Aminoguanidine-effects on endoneurial vasoactive nitric
oxide and on motor nerve conduction velocity in control
and streptozotocin-diabetic rats, Br. J. Pharm., 120, 593-
598.
29. Vlassara, H., Brownlee, M. and Cerami, A. (1983)
Excessive nonenzymatic glycosylation of peripheral and
central nervous system myelin components in diabetic rats,
Diabetes, 32, 670-674.
30. Sugimoto, K., Nishizawa, Y., Horiuchi, S. and Yagihashi,
S. (1997) Localization in human diabetic peripheral nerve
of Ne-carboxymethyllysine-protein adducts, an advanced
glycation endproduct, Diabetologia, 40, 1380-1387.
31. Vlassara, H., Brownlee, M. and Cerami, A. (1986)
Nonenzymatic glycosylation: role in the pathogenesis of
diabetic complications, Clin. Chem., 32, B37-B41.
32. Brownlee, M., Cerami, A. and Vlassara, H. (1988)
Advanced glycosylation end products in tissue and the bio-
chemical basis of diabetic complications, New Engl. J.
Med., 318, 1315-1321.
33. Cameron, N.E., Cotter, M.A. and Low, P.A. (1991) Nerve
blood flow in early experimental diabetes in rats: relation
to conduction deficits, Am. J. Physiol., 261, E1-E8.
34. Wright, R.A. and Nukada, H. (1994) Vascular and meta-
bolic factors in the pathogenesis of experimental diabetic
neuropathy in mature rats, Brain, 117, 1395-1407.
34 COPPEY, ET AL.
I NTERNATIONAL J OURNAL OF E XPERIMENTAL D IABETES R ESEARCH35. Coppey, L.J., Davidson, E.P., Dunlap, J.A., Lund, D.D.
and Yorek, M.A. (2000) Slowing of motor nerve conduc-
tion velocity in streptozotocin-induced diabetic rats is pre-
ceded by impaired vasodilation in arterioles that overlie
the sciatic nerve, Int. J. Exp. Diab. Res., 1, 131-143.
36. Terata, K., Coppey, L.J., Davidson, E.P., Dunlap, J.A.,
Gutterman, D.D. and Yorek, M.A. (1999) Acetylcholine-
induced arteriolar dilation is reduced in streptozotocin-
induced diabetic rats with motor nerve dysfunction, Br. J.
Pharm., 128, 837-843.
37. Kihara, M. and Low, P.A. (1995) Impaired vasoreactivity
to nitric oxide in experimental diabetic neuropathy, Exp.
Neurology, 132, 180-185.
38. Maxfield, E.K., Cameron, N.E. and Cotter, M.A. (1997)
Effects of diabetes on reactivity of sciatic vasa nervorum in
rats, J. Diabetes & Comp., 11, 47-55.
39. Fortes, Z.B., Becker, C., Oliveira, M.A. and Scivoletto, R.
(1996) Influence of aldose reductase inhibition on the
microvascular reactivity in experimental diabetes, Gen.
Pharmac., 27, 917-921.
40. Otter, D.J. and Chess-Williams, R. (1994) The effects of
aldose reductase inhibition with ponalrestat on changes in
vascular function in streptozotocin diabetes rats, Br. J
Pharm., 113, 576-580.
41. Wakasugi, M., Noguchi, T., Inoue, M., Tawata, M.,
Shindo, H. and Onaya, T. (1991) Effects of aldose reduc-
tase inhibitors on prostacyclin (PGI2) synthesis by aortic
rings from rats with streptozotocin-induced diabetes,
Prostaglandins, Leukotrienes and Essential Fatty Acids,
44, 233-236.
42. Cameron, N.E. and Cotter, M.A. (1992) Impaired contrac-
tion and relaxation in aorta from streptozotocin-diabetic
rats: role of polyol pathway, Diabetologia, 35, 1011-1019.
43. Tesfamariam, B., Brown, M.L. and Cohen, R.A. (1992)
Aldose reductase and myo-inositol in endothelial cell dys-
function caused by elevated glucose, J. Pharm. Exp.
Therap., 263, 153-157.
44. Tesfamariam, B., Palacino, J.J., Weisbrod, R.M. and
Cohen, R.A. (1993) Aldose reductase inhibition restores
endothelial cell function in diabetic rabbit aorta, J.
Cardiovasc. Pharm., 21, 205-211.
45. Keegan, A., Jack, A.M., Cotter, M.A. and Cameron, N.E.
(2000) Effects of aldose reductase inhibition on responses
of the corpus cavernosum and mesenteric vascular bed of
diabetic rats, J. Cardiovasc. Pharm., 35, 606-613.
46. Archibald, V., Cotter, M.A., Keegan, A. and Cameron,
N.E. (1996) Contraction and relaxation of aortas from
diabetic rats: effects of chronic anti-oxidant and
aminoguanidine treatments, Naunyn-Schmiedebergs Arch.
Pharm., 353, 584-591.
47. Ozyazgan, S., Unluccerci, Y., Bekpinar, S. and Akkan, A.G.
(2000) Impaired relaxation in aorta from streptozotocin-
diabetic rats: effect of aminoguanidine (AMNG) treatment,
Int. J. Exp. Diabetes Res., 1, 145-153.
48. Bucala, R. Tracey, K.J. and Cerami, A. (1991) Advanced
glycosylation products quench oxide and mediate defective
endothelium-dependent vasodilatation in experimental dia-
betes, J. Clin. Invest., 87, 432-438.
49. Crijns, F.R.L., Struijker Boudier, H.A. and Wolffenbuttel,
B.H.R. (1998) Arteriolar reactivity in conscious diabetic
rats: influence of aminoguanidine treatment, Diabetes, 47,
918-923.
50. Cameron, N.E., Cotter, M.A., Basso, M. and Hohman,
T.C. (1997) Comparison of the effects of inhibitors of
aldose reductase and sorbitol dehydrogenase on neurovas-
cular function, nerve conduction and tissue polyol path-
way metabolites in streptozotocin-diabetic rats,
Diabetologia, 40, 271-281.
51. Young, W. (1980) H2 clearance measurement of blood
flow: a review of technique and polarographic principles,
Stroke, 11, 552-564.
52. Coppey, L.J., Gellett, J.S., Davidson, E.P., Dunlap, J.A.,
Lund, D.D. and Yorek, M.A. (2001) Effect of antioxidant
treatment of streptozotocin-induced diabetic rats on
endoneurial blood flow, motor nerve conduction velocity
and vascular reactivity of epineurial arterioles of the sciatic
nerve, Diabetes, 50, 1927-1937.
53. Sell, D.R. and Monnier, V.M. (1989) Structure elucidation
of a senescence cross-link from human extracellular
matrix, J. Biol. Chem., 264, 21597-21602.
54. Lou, M.F., Dickerson, J.E. Jr, Garadi, R. and York, B.M.
Jr. (1988) Glutathione depletion in the lens of galac-
tosemic and diabetic rats, Exp. Eye Res., 46, 517-530.
55. Mihara, M., Uchiyama, M. and Fukuzama, K. (1980)
Thiobarbituric acid value of fresh homogenate of rat as a
parameter of lipid peroxidation in aging, CC14 intoxica-
tion, and vitamin E deficiency, Biochem. Med., 23, 302-
311.
56. Siman, C.M. and Eriksson, U.J. (1997) Vitamin C supple-
mentation of the maternal diet reduces the rate of malfor-
mation in the offspring of diabetic rats, Diabetologia, 40,
1416-1424.
57. Coppey, L.J., Gellett, J.S., Davidson, E.P., Dunlap, J.A.,
Lund, D.D., Salvemini, D and Yorek, M.A. (2001) Effect
of M40403 treatment of diabetic rats on endoneurial
blood flow, motor nerve conduction velocity and vascular
function of epineurial arterioles of the sciatic nerve, Br. J.
Pharm., 134, 21-29.
58. Vinik, A.I., Park, T.S., Stansberry, K.B. and Pittenger, G.L.
(2000) Diabetic neuropathies, Diabetologia, 43, 957-973.
59. Yagihasshi, S. (1995) Pathology and pathogenetic mecha-
nisms of diabetic neuropathy, Diabetes/Metabolism Rev.,
11, 193-225.
60. Stevens, M., Van Huysen, C., Beyer, L., Thomas, T. and
Yorek, M.A. (1996) Amelioration of nerve blood flow
deficits by myo-inositol in streptozotocin-diabetic rats,
Diabetes, 45, 210A.
61. Loy, A., Lurie, K.G., Ghosh, A., Wilson, J.M., MacGregor,
L.C. and Matschinsky, F.M. (1990) Diabetes and the myo-
inositol paradox, Diabetes, 39, 1305-1312.
62. Tomlinson, D.R. (1992) The pharmacology of diabetic
neuropathy, Diabetes/Metabolism Rev., 8, 67-84.
63. Ward, J.D. (1995) Biochemical and vascular factors in the
pathogenesis of diabetic neuropathy, Clin. Invest. Med.,
18, 267-274.
VASCULAR DYSFUNCTION IN DIABETIC NEUROPATHY 35
I NTERNATIONAL J OURNAL OF E XPERIMENTAL D IABETES R ESEARCH64. Cartledge, J.J., Eardley, I. and Morrison, J.F.B. (2001)
Advanced glycation end-products are responsible for the
impairment of corpus cavernosal smooth muscle relaxation
seen in diabetes, BJU International, 87, 402-407.
65. Bravenboer, B., Kappelle, A.C., Hamers, F.P.T., van Buren,
T., Erkelens, D.W. and Gispen, W.H. (1992) Potential use
of glutathione for the prevention and treatment of diabetic
neuropathy in the streptozotocin-induced diabetic rat,
Diabetologia, 35, 813-817.
36 COPPEY, ET AL.
I NTERNATIONAL J OURNAL OF E XPERIMENTAL D IABETES R ESEARCH